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A B S T R A C T   
The COVID-19 pandemic has had an unprecedented and devastating impact on public health, society and eco-
nomics around the world. As a result, the development of vaccines to protect individuals from symptomatic 
COVID-19 infections has represented the only feasible health tool to combat the spread of the disease. However, 
at the same time the development and regulatory assessment of different vaccines has challenged pharmaceutical 
industries and regulatory agencies as this process has occurred in the shorter time ever though. So far, two mRNA 
and two adenovirus-vectored vaccines have received a conditional marketing authorisation in the EU and other 
countries. This review summarized and discusses the assessment reports of the European Medicine Agency (EMA) 
concerning the safety of the 3 vaccines currently used in the EU (Pfizer, Moderna and Astra-Zeneca). A particular 
focus has been paid to safety information from pre-clinical (animal) and clinical (phase 3 trials) studies. Overall, 
the most frequent adverse effects reported after the administration of these vaccines consisted of local reactions 
at the injection site (sore arm and erythema) followed by non-specific systemic effects (myalgia, chills, fatigue, 
headache, and fever), which occurred soon after vaccination and resolved shortly. Rare cases of vaccine-induced 
immune thrombotic thrombocytopenia have been reported for Vaxzevria. Data on long-term studies, interaction 
with other vaccines, use in pregnancy/breast-feeding, use in immunocompromised subjects, and in subjects with 
comorbidities, autoimmune or inflammatory disorders are still missing for these vaccines. Therefore, careful 
follow-up and surveillance studies for continued vaccine safety monitoring will be needed to ascertain the po-
tential risks of such adverse events or diseases. In conclusion, the benefits and risks of current COVID-19 vaccines 
must be weighed against the real possibility of contract the disease and develop complications and long-term 
sequels; all this on the basis of the available scientific evidence and in the absence of unmotivated biases.   
1. Introduction 
The COVID-19 pandemic is a global crisis with a devastating health, 
social and economic impact that represents a major burden on world-
wide health systems, including the European Union (EU) [1,2]. The 
pandemic has had, and still has, a remarkable impact on the people’s 
lives, both at individual and societal level, resulting in psychological 
problems and health behaviour changes [3]. The dysregulation of the 
immune system as a result of chemical exposures and modern lifestyles 
has been considered to play a role for the development and spread of 
COVID-19 and its complications [4]. The pandemic is changing rapidly 
and requires different strategies to maintain clinical preventive services, 
including immunization, in order to avoid overloading health systems 
and their eventual collapse [3,5,6]. 
Most COVID-19 patients have mild symptoms, including dry cough, 
sore throat, fever or chills, muscle or body aches, and spontaneous 
shortness of breath or difficulty breathing. However, symptoms may 
differ with severity of disease, age and presence of comorbidity. Co-
morbid adults and elderly patients experience multiple complications, 
including pneumonia, acute respiratory distress syndrome (ARDS), 
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sepsis and septic shock, and acute kidney injury, which can be mani-
festations of a cytokine storm. Cardiomyopathy, arrhythmia, neurologic 
complications have also been reported as well as complications inherent 
to prolonged hospitalization [7,8]. Severe COVID infection has thus far 
resulted in almost 3 million deaths worldwide ([9] as of 10 April 2021). 
The development and administration of vaccines for COVID-19 help 
to protect individuals from becoming ill; however, it is not known how 
long the immunity produced by vaccines lasts until more time passes 
since people were first vaccinated [10]. COVID-19 vaccines may be 
effective in reducing community spread and/or preventing disease in 
individuals, particularly serious forms of the disease [11]. 
Two types of Covid-19 vaccines are widely used: a) genetic, using 
messenger RNA (mRNA) to cause the body to produce viral proteins; and 
b) viral vectored, which uses genetically modified viruses, such as 
adenovirus to carry sections of coronavirus genetic material [11]. Both 
Pfizer/BioNTech’s and Moderna’s vaccines are mRNA-based that pro-
duce the synthesis of a version of the spike (S) protein from the severe 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes 
COVID-19. mRNA vaccines elicit a potent immune response including 
antibodies and cytotoxic T-cells. The potency of these vaccines has been 
optimised by encapsulation of the mRNA into lipid nanoparticles 
(LNPs), which protects the mRNA from degradation by RNases [12]. 
However, these LNPs may also affect the distribution of the mRNA. 
Intramuscular administration of LNP-formulated mRNA vaccines results 
in transient local inflammation that drives recruitment of neutrophils 
and antigen presenting cells (APCs) to the site of delivery. These cells 
uptake LNPs and express the mRNA-encoded antigen which is further 
processed by the proteasome to generate peptide epitopes which are 
presented in the cell membrane. Subsequently, APC migrate to nearby 
draining lymph nodes where T-cell priming occurs [12,13]. Likewise, 
passive drainage of mRNA–LNPs through lymphatic vessels allows direct 
delivery of mRNA to the lymph nodes containing resident 
antigen-presenting cells and T-cells within them [14]. 
The use of mRNA vaccines against SARS-CoV-2 developed by Pfizer/ 
BioNTech and Moderna has raised concerns in the mass media and the 
public regarding their safety as this is the first time mRNA vaccines are 
used at global scale. In addition, the latest thrombotic events associated 
with the AstraZeneca/Oxford University vaccine have added concerns to 
the safety of Covid-19 vaccines. Concerns raised on whether the efficacy 
of the current vaccines used worldwide to prevent COVID-19 trans-
mission, complications and deaths outweigh the potential risk of un-
known long-term adverse effects has triggered a passionate scientific 
and societal debate [11]. 
This review summarized and discusses the assessment reports of the 
European Medicine Agency (EMA) concerning the safety of the 3 vac-
cines currently used in the EU (Fig. 1). A particular focus has been paid 
to safety information from pre-clinical (animal) and clinical (phase 2/3 
trials) studies; however, efficacy issues of these vaccines are beyond the 
scope of this review. The Janssen’s COVID-19 vaccine has not been 
considered in this review because the European Commission granted a 
conditional marketing authorisation very recently and vaccination 
campaigns will not start until mid-April 2021 at best. Other COVID-19 
vaccine candidates are currently in various stages of development to 
determine safety and efficacy: 184 in preclinical development and 85 in 
clinical development (detailed information on the landscape of candi-
date vaccines is compiled by the World Health Organisation (WHO) and 
can be accessed at its webpage https://www.who.int/publications/ 
m/item/draft-landscape-of-covid-19-candidate-vaccines). In particular, 
two vaccine candidates based on adenovirus expressing the full-length S 
protein have completed their phase 3 clinical trials, one developed in 
China, based on human adenovirus type 5 (Ad5) [15] and other in 
Russia, which combines recombinant human Ad26 and Ad5 in a pri-
me–boost vaccination regimen [16]. For more details on other vaccines, 
see Dai and Gao [17] and Kyriakidis et al. [18]. 
2. COVID-19 vaccines currently authorised and used in the 
European Union 
2.1. Pfizer BioNTech COVID-19 mRNA vaccine (Comirnaty) 
On December 21st, 2020, the EMA Committee for Medicinal Products 
for Human Use (CHMP) issued a positive opinion for granting a condi-
tional marketing authorisation to Pfizer/BioNTech Comirnaty vaccine. 
According to the publicly available EMA CHMP assessment report 
[19], three pivotal (preclinical) experimental toxicology studies were 
conducted in Wistar rats. Two of them were repeat-dose toxicity studies, 
one with 30 μg of the clinically relevant variant and other with 100 μg of 
another variant, and the third one was a developmental and reproduc-
tive toxicity (DART) fertility-embryo foetal development (EFD) study, 
wherein the human clinical dose (30 μg RNA/dose) was administered to 
female rats twice before the start of mating and twice during gestation. 
The main results of these studies are shown in Table 1. The liver effects 
were considered as non-relevant and attributed to the LNP where the 
mRNA was encapsulated. No vaccine-related effects were observed on 
Fig. 1. Diagram with the three vaccines against SARS-CoV-2 used currently used in vaccination campaigns in the EU.  
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female fertility, gestation, embryo-foetal or offspring development up to 
weaning. No genotoxicity studies were performed as the components of 
the vaccine formulation (LNPs and mRNA) are not expected to elicit 
genotoxic effects [19]. In particular, the delivered mRNA is active in the 
cytoplasm of a cell and it does not enter the nucleus or interact with the 
genome, such that it is non-replicating [20]. 
The safety evaluation conducted in humans consisted of one ongoing 
phase 2/3 clinical trial which included 21,720 subjects who received 
two doses of the vaccine (30 μg of mRNA) and 21,728 individuals in the 
placebo group, who were followed-up over 2 months (Table 2). The most 
frequent adverse events were local reactions, consisting of pain at the 
injection side, less frequently redness and swelling, and very rarely 
lymphadenopathy. These were considered most often vaccine typical 
reactions, which appeared 1− 3 days after vaccination and persisted for 
1− 2 days. The systemic reactions more frequently reported were fatigue 
and headache, followed by myalgia and chills, arthralgia and fever (<15 
%) (Table 2). The frequency of headache, fatigue and fever was higher 
after the second dose in both age groups (16− 55 and >55 years). These 
events were reported within 7 days after the first or second dose and 
were largely attributable to reactogenicity events. None immediate 
adverse event, occurring within 30 min after dosing and indicative of an 
allergic reaction to vaccine, was reported. However, three cases of 
anaphylaxis were reported during vaccination campaigns by the time 
the EMA assessment report was written [19]. 
Serious adverse events and deaths occurred in a small number of 
subjects and were balanced in both study arms and in the two age 
groups. However, none of the deaths were considered related to study 
intervention. Both local and systemic reactions were transient, of mild to 
moderate intensity, and resolved within a few days after vaccination. 
Table 1 
Pivotal non-clinical experimental toxicology studies conducted by applicants on 
the three vaccines under consideration.   
Pfizer/BioNTech Moderna Astra-Zeneca 
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Table 1 (continued )  
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APTT: activated partial thromboplastin time. 
GGT: Gamma-glutamyl transferase. 
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ALP: alkaline phosphatase. 
BUN: blood urea nitrogen. 
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They were milder and of slightly lower frequency among subjects >55 
years of age. They were attributable to reactogenicity to the vaccine as 
the reactogenicity profile was similar to that of any authorised vaccine 
[19]. 
2.2. Moderna COVID-19 vaccine (mRNA-1273) 
On January, 6th 2021, the EMA CHMP issued a positive opinion for 
granting a conditional marketing authorisation to Moderna COVID-19 
vaccine [21]. 
The results of the preclinical (regulatory toxicology) studies are 
shown in Table 1. Overall, these are roughly similar to those reported for 
the Pfizer/BioNTech vaccine. Six repeated-dose GLP-compliant studies 
were performed in Sprague Dawley rats, with a dose range from 9 to 150 
μg mRNA/dose (Table 1). The results were quite similar among the 
studies, supporting that observed toxicities were not product specific, 
but rather caused by the immunologic responses towards the translated 
antigens, and potentially by a contribution of the novel LNP formula-
tion. A local inflammatory response was not only noted in the direct 
vicinity of the injection site, but also in adjacent tissues and/or organs 
[21]. 
The genotoxic potential of the final vaccine formulation and a novel 
excipient (one of the four lipids that protect and carry the mRNA in LNP) 
was evaluated. The test used consisted of a bacterial reverse mutation 
test, in vitro mammalian cell micronucleus test in human peripheral 
blood lymphocytes, and in vivo mammalian bone marrow erythrocyte 
micronucleus assay in the rat. The results indicated that a relevant 
genotoxic risk was not expected for mRNA-1273. A GLP-compliant 
DART study was conducted in female Sprague Dawley CD rats. No 
mRNA-1273-related effects were observed on female fertility, embryo- 
foetal or post-natal survival, growth or development in the offspring 
[21]. 
Table 2 
Safety evaluation in humans conducted in randomized clinical trials by appli-
cants on the three vaccines under consideration.   
Pfizer BioNTech Moderna Astra-Zeneca 
Dose 30 μg of mRNA 100 μg of mRNA 5 × 1010 vp  
x 2 doses x 2 doses x 2 doses 
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Concerning the human studies on clinical safety, 15,185 subjects 
were enrolled in the vaccine group of the pivotal phase 3 trial and 
15,166 in the placebo group, with a median follow-up of 63 days after 
the second injection (Table 2). Overall, qualitative findings were 
roughly similar to those observed by Pfizer-BioNTech, with minor dif-
ferences in the frequency of some local and systemic adverse reactions 
(reactogenicity). A higher incidence of lymphadenopathy, chills, 
arthralgia and nausea was reported with Moderna’s vaccine, particu-
larly after the second dose [21]. Remarkably, delayed local reactions at 
the injection-site characterised by erythema, induration, and tenderness 
have been reported by in 244 participants (0.8 %) after the first dose and 
in 68 participants (0.2 %) after the second dose of the phase 3 clinical 
trial [22]. 
Regarding more serious adverse events of the nervous system, 3 ce-
rebrovascular accidents, 2 embolic strokes and 1 transient ischaemic 
attack were reported in the vaccine arm, whereas the placebo group 
showed 1/0/0, respectively. Furthermore, there were 2 reports of deep 
vein thrombosis in the vaccine group and none in the placebo. Detailed 
background information for stroke and transient ischaemic attack indi-
cated a significant medical history or increased risk for these events 
[21]. Conversely, no similar events were reported for the Pfi-
zer/BioNTech vaccine [19]. 
2.3. Astra-Zeneca COVID-19 vaccine (Vaxzevria - AZD1222) 
On January, 29th 2021, the EMA CHMP issued a positive opinion for 
granting a conditional marketing authorisation to Astra-Zeneca. COVID- 
19 vaccine AZD1222 is a monovalent vaccine composed of a single re-
combinant, replication-deficient chimpanzee adenovirus (ChAdOx1) 
vector that has been modified to contain the gene encoding the Spike (S) 
glycoprotein of SARS CoV-2 [23]. 
Regarding non-clinical data to address the concerns raised for the 
purpose of granting a conditional marketing authorisation, three GLP 
compliant repeated-dose studies were performed in mice using the same 
(ChAdOx1) or a closely related platform to support the safety of the 
vaccine. Mice were considered a relevant species for toxicity assessment 
as they develop an immune response to the vaccine antigen. Two doses 
of the respective vectors were administered intramuscularly with a 14 
day-interval, followed by a 13-day observation period. In addition, a 
pivotal repeated-dose toxicity study was conducted in mice by admin-
istering control or test item on days 1, 22 and 43, followed by a recovery 
period of 28 days (Table 1). The local effects observed in the toxicity 
study were considered non-adverse and related to the pharmacological 
immune-related effects of the vector administration. The minor changes 
reported for haematology and clinical chemistry parameters were 
consistent with the expected pharmacology effects and disappeared after 
the recovery period [23]. 
No genotoxicity and carcinogenicity studies were carried out as these 
studies are normally not required for viral vaccines according to relevant 
guidelines, and no adjuvants or novel excipients are used in this vaccine. 
A preliminary DART study failed to observe adverse effects related to the 
vaccine on female reproduction, foetal or pup survival and no foetal 
visceral or skeletal findings were observed either. The results indicated 
sufficient transfer of anti-S glycoprotein antibody via placenta and 
lactation. The main and definitive DART study in mice is ongoing and 
the results will be provided to EMA. Adenovirus infections are prevalent 
worldwide and wild-type adenoviral infection in pregnant women is 
generally not associated with congenital anomalies [23]. 
The clinical safety of AZD1222 is based on the interim analysis of the 
results from four individual studies pooled comprising 12,021 subjects 
receiving any dose of the vaccine and 11,724 the placebo. The median of 
duration of follow-up was 55.6 days after the second dose. Local and 
systemic adverse events were generally milder and reported less 
frequently after the second dose than after the first dose. Adverse events 
were less frequently reported in adults aged ≥ 65 than adults aged 18–65 
[23]. 
Local and systemic adverse events are shown in Table 2. The majority 
of events was of mild to moderate severity, occurred within ≤ 7 days of 
any dose and were less frequently observed after the second dose. In 
relation to adverse events of special interest, their overall incidence was 
low: 0.8 % in the vaccine group and 1.1 % in the placebo. Less than 0.1 
% participants reported serious adverse events considered treatment 
related, 3 in the vaccine group (fever, increased C-reactive protein, and 
myelitis transverse) and 2 in the control group (autoimmune haemolytic 
anaemia and myelitis). One case of multiple sclerosis was considered 
unrelated to the vaccine as new and pre-existent brain lesions were 
observed in the Magnetic Resonance Imaging. Other neurological 
serious adverse events in both the vaccine group and the placebo were 
facial spasm, migraine, ischaemic stroke, presyncope, syncope, seroto-
nin syndrome, subarachnoid haemorrhage and transient ischaemic 
attack. However, only facial spasm and migraine may be potentially 
related to the intervention [23]. 
3. Thrombosis associated with thrombocytopenia in subjects 
vaccinated with Vaxzevria (COVID-19 vaccine AstraZeneca) 
Overall, the number of cases of thrombosis reported after vaccination 
with Vaxzevria in relation to the number of people vaccinated is less 
than the number of these events that occur in the general population, 
thereby the administration of this vaccine is not considered to be asso-
ciated with an increased risk of thrombotic events. However, very rare 
cases of thrombosis combined with thrombocytopenia, and sometimes 
bleeding, have been reported [24]. These events included cerebral 
venous sinus thrombosis (CVST) and splanchnic vein thrombosis (SVT) 
and have been referred to as vaccine-induced immune thrombotic 
thrombocytopenia (VITT) [25,26]. 
According to the EMA’s Pharmacovigilance Risk Assessment Com-
mittee (PRAC), from the 34 million people that received the vaccine in 
the European Economic Area (EEA) and the UK as of April 4th 2021, 169 
cases of CVST and 53 cases of SVT were reported to EudraVigilance, with 
most of them occurring within the first two weeks of vaccination in 
women <60 year. The estimated incidence of this rare adverse effect is 
around 1 in 100,000 people under the age of 60 [24]. The comparison of 
the number of reported cases of VITT with their incidence rate in the 
general population has shown higher numbers in the pool of all vacci-
nated people, but not in older people. However, with the available ev-
idence it has not been possible to identify specific risk factors. While a 
causal link with the vaccine has not been proven at this time, this con-
dition deserves further analysis as it might be possible. Accordingly, it 
should be listed as very rare side effects of Vaxzevria [24]. 
Since VITT clinically resembles autoimmune heparin-induced 
thrombocytopenia (HIT, a rare clotting disorder affecting 1–2% of pa-
tients treated with heparin), an immune response has been suggested as 
potential pathomechanism. HIT is caused by antibodies that recognize 
complexes formed when negatively charged carbohydrates present in 
heparin molecules bind to a positively charged platelet protein (platelet 
factor 4, PF4), which plays an important for clotting [27]. Two recent 
case-series studies have shown that the serum of patients with VITT has 
high levels of antibodies to PF4–polyanion complexes [25,26]. It has 
been suggested that the vaccination might induce the formation of au-
toantibodies against PF4 as part of the inflammatory reaction and im-
mune stimulation of vaccination. These antibodies would then cause 
massive platelet activation via the Fc receptor as also occurs with HIT 
[25,28]. Despite DNA and RNA can form multimolecular complexes 
with PF4 [25], VITT has been reported thus far only with 
adenovirus-vectored vaccines (Vaxzevria and Janssen vaccine) but not 
with mRNA vaccines. 
Notwithstanding the above, the EMA’s PRAC statement issued on 
April 7th 2021 considered that the overall benefits of Vaxzevria in pre-
venting COVID-19 disease outweigh the risks of side effects and rec-
ommended healthcare professionals to warn people receiving the 
vaccine to seek medical attention if they develop symptoms suggestive 
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of these rare conditions [24]. 
Notably, no signal has been identified so far from monitoring for 
other COVID-19 vaccines, but close safety monitoring is warranted. 
However, a number of thrombocytopenia (particularly immune throm-
bocytopenia, ITP) events have been reported after administration of 
mRNA vaccines in the US. In a series of 20 patients recently published 
[29], nine received the Pfizer-BioNTech vaccine and 11 the Moderna 
vaccine. The question of whether these cases are actually primary ITP 
coinciding with the administration of the vaccine or ITP secondary to 
vaccination remains unanswered. If the latter is true, this means an 
incidence of 1 case in a million vaccinated persons in the US. Compar-
atively, approximately 50,000 adults are diagnosed with ITP in the US 
each year and 1 case in 40,000 children develops secondary ITP after 
receiving measles-mumps-rubella vaccine [29]. 
It should be noted that a distinctive characteristic of SARS-CoV-2 
infection is vascular damage, leading to severe endothelial injury, 
increased vascular permeability, microvascular occlusion and coagul-
opathy, which can manifest as venous and arterial thrombotic events. In 
the context of hyperinflammation, a serious malfunction of cytokine- 
controlled coagulation can occur resulting in thromboembolic events 
associated with higher mortality rate in COVID-19 patients [30,31]. 
Importantly, a systematic review has reported a very high incidence of 
thrombotic complications in 34 % of COVID-19 patients admitted to ICU 
despite anticoagulant thromboprophylaxis [32]. Although these events 
represent a well-known complication of any serious infection, additional 
mechanisms such as endothelial damage, increased vascular perme-
ability and microvascular occlusion may be implicated in COVID-19. 
4. General discussion 
Two mRNA and two adenovirus-vectored vaccines have received a 
conditional marketing authorisation in the EU and other countries. This 
authorisation has been granted in the interest of public health because 
the benefit of immediate availability outweighs the risk from less 
comprehensive data than normally required. In clinical trials, these 
vaccines have shown very high levels of protection against symptomatic 
infections with COVID-19 [33]. 
The S protein of SARS-CoV-2 is a major target of virus neutralizing 
antibodies. Indeed, it has become a key antigen for vaccine development 
as this protein is intended to trigger a strong and relatively long-lasting 
production of high affinity virus neutralizing antibodies, which block 
the S-protein and its receptor-binding domain (RBD) interaction [34]. 
However, these vaccines are also expected to elicit a concomitant T-cell 
response of the Th1 type, supporting the B-cells responsible for the 
production of S-specific antibodies and cytotoxic T-cells that kill virus 
infected cells [19]. 
4.1. Non clinical (animal) studies 
According to the EMA’s assessment reports, the results of the non- 
clinical (animal) studies conducted by applicants for the three vac-
cines considered in this review failed to reveal any major or special 
hazard for humans regarding conventional studies of repeated dose 
toxicity, genotoxicity and reproductive and developmental toxicity. 
However, it should be noted that the absence of dose-response designs in 
the studies increases the difficulty to interpret the effects. In addition, 
since no long-term animal studies were conducted due to the need of 
urgent development of the vaccines, the authorization issued was 
restricted to emergency use. 
4.2. Adverse reactions 
Overall, the most frequent adverse effects reported after the 
administration of the three vaccines considered in this review consisted 
of local reactions at the injection site (sore arm and erythema) followed 
by non-specific systemic effects (myalgia, chills, fatigue, headache, and 
fever). These adverse reactions are considered as the result of the im-
mune system’s reaction that occurs soon after vaccination (also referred 
to as reactogenicity) and resolves shortly [35]. Given the scale-up of 
mass vaccination campaigns across the world, severe adverse events 
may occur and will likely generate concerns among patients and re-
quests for evaluation. 
Severe allergic reactions due to anaphylaxis represent a very rare 
side effect associated with most vaccines, including mRNA vaccines. For 
this reason, it has been recommended that subjects with a previous 
history of severe allergic reactions to any vaccine ingredient should not 
receive it [36]. This safety concern is currently followed-up via routine 
pharmacovigilance. 
Long-term safety data, interaction with other vaccines, data on use in 
pregnancy/breastfeeding and other vulnerable subgroups (e.g., patients 
with co-morbidities such as chronic obstructive pulmonary disease, 
diabetes, chronic neurological disease, or cardiovascular disorders), 
immunocompromised patients and subjects with autoimmune or in-
flammatory disorders were missing. However, such information will be 
collected in the post-authorisation safety studies and in ongoing pivotal 
studies where the studied population will be followed-up for up to 2 
years, as this is a specific obligation of a conditional marketing autho-
rization. These studies will also address potential risks specific to 
vaccination for COVID-19 (e.g. vaccine-associated enhanced respiratory 
disease) [19,21,23]. 
The phase 3 clinical trials of all COVID-19 vaccines conducted in 
several countries with different numbers of volunteers mainly focused 
on immunogenicity and safety, and primarily reported the side effects 
and adverse events that arose shortly after vaccination. Despite the 
limitations of those trials (neither all population subgroups nor long- 
term adverse events are covered), they have the advantage of using a 
vaccine arm and a control arm, which enables to assess whether there is 
a numerical imbalance between the vaccine group compared with the 
placebo group. Further information about the current status of ongoing/ 
approved clinical trials of COVID-19 vaccines can be accessed at https:// 
clinicaltrials.gov/. 
Since potential long-term adverse effects (mediated by immune or 
non-immune mechanisms) cannot be ruled out with the three COVID-19 
vaccines mentioned above, careful follow-up and surveillance studies 
for continued vaccine safety monitoring will be needed to ascertain the 
potential risks of such adverse events or diseases [37]. 
It is important to note that vaccination campaigns are carried out in a 
different context than phase 3 clinical trials, in the sense that a control 
group (i.e., placebo) is not available. Thereby, any new serious adverse 
event that may occur shortly after vaccination does not necessarily have 
to be considered as secondary to vaccination, but may actually be a 
primary event (or disease) coincident with the administration of the 
vaccine. A thorough assessment of each case should be conducted in 
relation to the subjects’ medical history, current and past treatments, 
and investigation of the genetic background, if appropriate. 
According to the 4th Pharmacovigilance Report on COVID-19 Vac-
cines of the Spanish Agency for Medicines and Health Products 
(AEMPS), at the time of the latest data cut-off (March 21st, 2021) a total 
of 6,125,119 doses of COVID-19 vaccines had been administered in 
Spain since the beginning of the vaccination campaign (December 27th, 
2020). A total of 4,136,963 people were vaccinated of which 67 % were 
women. Seventy nine percent of the administered doses corresponded to 
Comirnaty, 16 % to Vaxzevria and 5% to Moderna vaccine, and 11,182 
adverse events were reported, 93 % in people between 18 and 65 years 
old (93 %) and mostly women (82 %) [38]. The most frequently reported 
events continue to be general disorders (fever, pain at the injection site), 
events of the central nervous system (headache, dizziness) and muscu-
loskeletal (myalgia and arthralgia) (Table 3). The report concluded that, 
after reviewing the available data, no hitherto unknown adverse re-
actions have been identified that may give cause for concern [38]. 
However, no information is available so far on potential long-term 
adverse events. 
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According to the UK Medicines and Healthcare products Regulatory 
Agency, more than 30 Million doses of vaccines had been administered 
as of 28 March 2021 (10.9 and 19.5 million first doses of the Pfizer/ 
BioNTech and AstraZeneca vaccines, respectively). A total of 43,491 
Yellow Cards were received and analysed for the Pfizer/BioNTech vac-
cine and 116,162 for the AstraZeneca vaccine [33]. These reports 
included 124,371 and 440,871 suspected reactions, respectively 
(although a single report may contain more than one symptom). Table 4 
summarised the main adverse effects reported. 
In contrast to the limited evidence of serious adverse effects of 
COVID-19 vaccines mentioned above, there is growing evidence that 
health consequences of COVID-19 extend far beyond acute infection (the 
so-called persistent COVID-19, post-acute COVID-19 syndrome or late 
squeals of the disease) as reported in patients followed-up for 9 months 
after illness. Approximately 30 % reported persistent symptoms, despite 
undergoing mild illness [39]. Two categories have been reported: a) 
subacute or ongoing symptomatic COVID-19, which extent from 4 to 12 
weeks beyond acute COVID-19; and b) chronic or post-COVID-19 syn-
drome, which extent beyond 12 weeks of the onset of acute COVID-19 
and are not attributable to alternative diagnoses. The main symptoms 
and abnormalities correspond to respiratory, haemetological, cardio-
vascular, neuropsychiatric, renal, endocrine, gastrointestinal, hep-
atobiliary, and dermatologic alterations [40]. 
EMA and competent authorities of EU Member States have devel-
oped a safety monitoring plan for COVID-19 vaccines (i.e., a guidance on 
good pharmacovigilance practices) with the aim of collecting and 
rapidly reviewing new information emerging from the outcome of the 
COVID-19 vaccination campaigns currently in place. This plan will 
allow the EU Medicines Regulatory Network to assess safety data arising 
from spontaneous reports, observational studies, etc. Thus, any potential 
safety concerns identified will be addressed by implementing appro-
priate regulatory measures to protect individual and public health under 
a transparent and timely manner [41]. 
4.3. Non-pharmacological measures during the vaccination campaigns: 
possible scenarios for the evolution of the COVID-19 pandemic 
A recent study presented a mathematical model structured according 
to age, adapted to a series of epidemiological data from the United 
Kingdom, to estimate the dynamics of the SARS-CoV-2 virus in 2021, 
based on scenarios of relaxation of non-pharmacological interventions 
and characteristics vaccines [42]. Another study estimated that vacci-
nation is insufficient to control the outbreak caused by COVID-19. 
Elimination of all non-pharmacological interventions after the end of 
the vaccination program will lead to 21,400 deaths due to the virus, in 
the case of a vaccine that prevents 85 % of infections, and the number 
increases to 96,700 deaths if the vaccine prevents only 60 % of infections 
(estimated by January 2024) [43]. 
However, although vaccination of the most vulnerable groups will 
allow some relaxation of control measures, this must be done gradually 
in order to mitigate the large-scale consequences for public health [11]. 
For the prediction of the number of daily deaths mentioned previously, 
the specialists used data from the United Kingdom (a death caused by 
COVID-19 was considered as the death that occurred within 28 days of a 
positive SARS-CoV-2 test). Experts point out that the actual number of 
deaths could be much higher. Prioritizing older groups and vulnerable 
people would lead to the greatest reduction in deaths. 
The high efficacy of vaccines is a long-term key element. Although 
mass vaccination will significantly reduce the spread of the disease, 
other measures will be needed, such as periodic testing, disease pro-
gression monitoring and isolation strategies. 
At the same time, for longer periods, there is a likelihood of a 
decrease in the degree of immunization of patients. As a result, the need 
to implement seasonal vaccination programs against SARS-CoV-2 is 
anticipated, mainly protecting the most vulnerable, similar to seasonal 
influenza vaccination [44]. 
Some medical experts believe that the SARS-CoV-2 virus can become 
a seasonal flu-like infection, while others believe it is more likely to 
circulate at low levels for years, with the potential for recurrence of 
outbreaks, which could be complicated by new viral strains. The end of 
the pandemic would be to stop the threat of increasing the number of 
infections and severe forms of the disease, which put a lot of pressure on 
health systems. The timing of pandemic control and a gradual return to 
normalcy depends on how quickly people around the world are vacci-
nated. For example, through a combination of mass vaccination and 
acquired immunity from infection, the US and Europe can aim for a 
"return to normal" with some minimal disease control measures. But this 
could take longer in Asia, where low rates of infection in some places 
mean that populations need to rely on a high vaccination rate to achieve 
collective immunity (when at least two-thirds of the population is im-
mune to the virus). At that point, the virus will likely continue to 
circulate for many years, but will not pose a major threat to health 
systems [45]. 
Experts believe that the end of the pandemic will be less defined than 
its beginning, as countries will be able to control the transmission of the 
virus at different times. But they agree that although vaccines have been 
Table 3 
List of the 10 most reported adverse events of the 3 COVID-19 vaccines that are 
currently being administered in Spain.   
Vaccine  
Comirnaty Moderna Vaxzevria 
Adverse Event 4,834,876* 304,715* 985.528* 
Pyrexia 41 % 50 % 66 % 
Headache 30 % 31 % 44 % 
Myalgia 22 % 23 % 31 % 
Pain at the injection site 14 % 15 % 13 % 
Malaise 13 % 10 % 15 % 
Nausea 9% 11 % 12 % 
Chills 8% 12 % 19 % 
Arthralgia 8% 8% 9% 
Fatiga 8% 8% 14 % 
Lymphadenopathy 7% 7% – 
Dizziness – – 11 %  
* Number of doses administered until March 21st, 2021. 
Source: 4th Pharmacovigilance Report of the AEMPS [38] 
Table 4 
List of the most common suspected reactions reported for the two COVID-19 
vaccines that are currently being administered in UK (as of March 28th, 2021).   
Comirnaty a Vaxzevria b 
Suspected reactions Total Fatal Total Fatal 
Blood Disorders 3698 1 3030 2 
Cardiac Disorders 1567 43 4325 57 
Ear Disorders 1235 0 3261 0 
Eye disorders 1897 0 5521 0 
Gastrointestinal disorder 13,387 15 46,391 6 
General disorders 36,796 127 151,940 205 
Immune system disorders 689 1 1314 1 
Infections 2864 55 8705 52 
Metabolic disorders 777 1 5353 3 
Muscle and tissue disorders 16,718 0 54,853 0 
Nervous system disorders 23,534 21 95,234 63 
Psychiatric disorders 1942 0 8047 1 
Renal and urinary disorders 311 2 1248 1 
Reproductive and breast disorders 672 0 1136 0 
Respiratory disorders 5200 25 12,660 52 
Skin disorders 8974 1 24,605 1 
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developed in record time, the virus will continue to exist [46]. 
The health and economic burden of COVID-19 has resulted in a high 
prevalence of the disease and socioeconomic costs. The huge amount of 
economic resources invested in scientific research has accelerated the 
development of COVID-19 vaccine candidates at a rate never seen 
before. This expense has been worth because of the impact of vaccines 
on individual and public health, health costs and the wider economy. A 
recent study has modelled the COVID-19 disease transmission and its 
economic impact to gain insight on potential future post-vaccination 
scenarios in particular how to achieve a best-case health and eco-
nomic scenario [47]. According to this study, a safe and effective 
COVID-19 vaccine not only will save lives and reduce costs of the health 
sector but also will mitigate the impact on the economy by avoiding 
physical distancing and the consequences thereof. 
5. Conclusion 
The three COVID-19 vaccines considered in this review did not 
reveal any major hazard based on conventional animal studies of 
repeated dose toxicity, genotoxicity and reproductive and develop-
mental toxicity; however, no long-term studies have been conducted 
because of the urgent development of the vaccines. In phase 3 clinical 
trials, the most frequent adverse effects reported consisted of local re-
actions at the injection site and, to a lesser extent, non-specific systemic 
effects. These common and expected adverse reactions (reactogenicity) 
occur shortly after vaccination and resolve in a few days, and represent 
the early reaction of the immune system after vaccination. Conversely, 
serious adverse events involving different organs/systems are quite 
uncommon and mostly balanced between vaccine and placebo groups. 
However, data on long-term safety data, interaction with other vaccines, 
data on use in pregnant or breastfeeding women, immunocompromised 
patients and other vulnerable subgroups are still missing and therefore 
pivotal studies are still ongoing to cover a follow-up period of 2 years. 
Although the administration of the Vaxzevria vaccine does not lead to an 
increased overall risk of thrombotic events, very rare cases of cerebral 
venous sinus thrombosis and splanchnic vein thrombosis accompanied 
by low platelet levels have been reported, which are currently under 
investigation and close surveillance. The benefits and risks of current 
COVID-19 vaccines must be weighed against the real possibility of 
contracting the disease and developing complications and long-term 
sequels. Given the high public interest and social alarm that this infor-
mation generates when it appears in the mass media, health pro-
fessionals and health authorities must adequately and timely inform the 
population about a sensitive issue such as COVID-19. 
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